Repligen reports Q3 revenue up 11%, completes BioLife acquisition, raises 2026 revenue guidance.

Repligen Corporation reported third quarter 2026 revenue of $209 million, an 11% increase year-over-year driven by strong organic growth and diversified portfolio demand. The company completed its acquisition of BioLife Solutions, enhancing its position in the cell therapy market and expects to realize cost synergies. Repligen raised its full-year 2026 revenue guidance to $844-$852 million, reflecting confidence from strong performance and acquisition benefits. The company also opened a new training center in South Korea, emphasizing its commitment to key biologics markets.

Repligen Corporation holds a market cap of $11.44 billion on Pluang as of Oct 27, 2026, 18:11 WIB, with a trading volume of 1,176,930 shares and an enterprise value of $11.32 billion. The stock price is currently USD 177.76, down 1.24% on the day. This trading activity reflects investor response to the company’s recent acquisition and updated revenue guidance.